

Clinical Oversight Review Board (CORB) Criteria for Prescribing Tafasitamab-cxix (Monjuvi)

Non-Formulary **tafasitamab-cxix (Monjuvi)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria and criteria for current OR new Kaiser Permanente members already taking the medication who have not been reviewed previously:

Non-formulary **tafasitamab-cxix (Monjuvi)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by Hematology/ Oncology provider
- Patient is at least 18 years of age
- Diagnosis of relapsed/ refractory CD19+ diffuse large B-cell lymphoma
- Patient has lack of response at least 2 prior lines of systemic therapy
- Patient has documented intolerance to Loncastuzimab (Zynlonta)
- Patient is ineligible for autologous stem cell transplant (ASCT)
- Patient will receive tafasitamab-cxix in combination with lenalidomide (Revlimid) for a maximum of 12 cycles, followed by tafasitamab-cxix monotherapy until disease progression or unacceptable toxicity